A Signature Identifies TIM-3 and VISTA As Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2023 Mar 27

PMID 36968142

Authors

Vigdis Nygaard

Anne Hansen Ree

Vegar Johansen Dagenborg

Anne-Lise Borresen-Dale

Bjorn Edwin

Asmund Avdem Fretland

Krzysztof Grzyb

Mads H Haugen

Gunhild M Maelandsmo

Kjersti Flatmark

Affiliations

Soon will be listed here.

Abstract

Significance: CLM is an important cause of colorectal cancer mortality where the majority of patients have yet to benefit from immunotherapies. In this study of gene expression profiling analyses, we uncovered novel immune checkpoint targets in a subgroup of patients with MSS CLMs harboring a mesenchymal phenotype.

Citing Articles

Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review.

Ashouri K, Wong A, Mittal P, Torres-Gonzalez L, Lo J, Soni S Cancers (Basel). 2024; 16(16).

PMID: 39199569 PMC: 11353018. DOI: 10.3390/cancers16162796.

PRRX1-OLR1 axis supports CAFs-mediated lung cancer progression and immune suppression.

Sun Y, Ying K, Sun J, Wang Y, Qiu L, Ji M Cancer Cell Int. 2024; 24(1):247.

PMID: 39010054 PMC: 11251326. DOI: 10.1186/s12935-024-03436-9.

Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.

Di Matteo S, Bilotta M, Pelosi A, Haas D, Theinert T, Weber G Front Immunol. 2024; 15:1382931.

PMID: 38736882 PMC: 11082345. DOI: 10.3389/fimmu.2024.1382931.

References

Su S, Wu W, He C, Liu Q, Song E . Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages. Oncoimmunology. 2015; 3(8):e953418. PMC: 4292267. DOI: 10.4161/21624011.2014.953418. View

Amoroso M, Matassa D, Agliarulo I, Avolio R, Lu H, Sisinni L . TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition. Cell Death Dis. 2016; 7(12):e2522. PMC: 5260997. DOI: 10.1038/cddis.2016.400. View

Shayan G, Srivastava R, Li J, Schmitt N, Kane L, Ferris R . Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology. 2017; 6(1):e1261779. PMC: 5283618. DOI: 10.1080/2162402X.2016.1261779. View

Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y . Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009; 15(3):195-206. DOI: 10.1016/j.ccr.2009.01.023. View

Loboda A, Nebozhyn M, Watters J, Buser C, Shaw P, Huang P . EMT is the dominant program in human colon cancer. BMC Med Genomics. 2011; 4:9. PMC: 3032646. DOI: 10.1186/1755-8794-4-9. View

Page A, Cosgrove D, Herman J, Pawlik T . Advances in understanding of colorectal liver metastasis and implications for the clinic. Expert Rev Gastroenterol Hepatol. 2014; 9(2):245-59. DOI: 10.1586/17474124.2014.940897. View

Yan Y, Zhang J, Li J, Liu X, Wang J, Qu H . High tumor-associated macrophages infiltration is associated with poor prognosis and may contribute to the phenomenon of epithelial-mesenchymal transition in gastric cancer. Onco Targets Ther. 2016; 9:3975-83. PMC: 4935103. DOI: 10.2147/OTT.S103112. View

Fretland A, Kazaryan A, Bjornbeth B, Flatmark K, Andersen M, Tonnessen T . Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial. Trials. 2015; 16:73. PMC: 4358911. DOI: 10.1186/s13063-015-0577-5. View

Sheffer M, Bacolod M, Zuk O, Giardina S, Pincas H, Barany F . Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A. 2009; 106(17):7131-6. PMC: 2678450. DOI: 10.1073/pnas.0902232106. View

10.

Mao L, Li Y, Zhao J, Li Q, Yang B, Wang Y . Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition. Oncol Lett. 2017; 14(1):647-654. PMC: 5494727. DOI: 10.3892/ol.2017.6209. View

11.

Bonde A, Tischler V, Kumar S, Soltermann A, Schwendener R . Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer. 2012; 12:35. PMC: 3314544. DOI: 10.1186/1471-2407-12-35. View

12.

Wang R, Song S, Harada K, Amlashi F, Badgwell B, Pizzi M . Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2019; 69(1):18-31. PMC: 6943252. DOI: 10.1136/gutjnl-2018-318070. View

13.

Groger C, Grubinger M, Waldhor T, Vierlinger K, Mikulits W . Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One. 2012; 7(12):e51136. PMC: 3519484. DOI: 10.1371/journal.pone.0051136. View

14.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

15.

Shi J, Huo R, Li N, Li H, Zhai T, Li H . CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer. 2019; 19(1):1140. PMC: 6878653. DOI: 10.1186/s12885-019-6321-x. View

16.

Chen L, Gibbons D, Goswami S, Cortez M, Ahn Y, Byers L . Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5:5241. PMC: 4212319. DOI: 10.1038/ncomms6241. View

17.

Pantaleo M, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G . Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer. 2008; 99(10):1729-34. PMC: 2584956. DOI: 10.1038/sj.bjc.6604681. View

18.

Findlay V, Wang C, Watson D, Camp E . Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 2014; 21(5):181-7. PMC: 4041800. DOI: 10.1038/cgt.2014.15. View

19.

Mak M, Tong P, Diao L, Cardnell R, Gibbons D, William W . A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2015; 22(3):609-20. PMC: 4737991. DOI: 10.1158/1078-0432.CCR-15-0876. View

20.

Ostrup O, Dagenborg V, Rodland E, Skarpeteig V, Silwal-Pandit L, Grzyb K . Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget. 2017; 8(44):76290-76304. PMC: 5652706. DOI: 10.18632/oncotarget.19350. View